Symbolbild · KI-generiert
X4 Pharmaceuticals, Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. Market capitalisation is an order of magnitude as of the date shown, not a real-time figure. The size class follows the thresholds in common use (micro < $300m, small < $2bn, mid < $10bn) and is meant as an indication, not a definition.
Company profile
X4 Pharmaceuticals develops therapies for rare diseases with a focus on the CXCR4 signalling pathway, which plays a central role in immune system regulation. The lead candidate Mavorixafor targets WHIM syndrome and other primary immunodeficiencies. The company has received FDA approval for Mavorixafor in the United States for WHIM syndrome.
Short profile generated automatically and checked for plausibility. A full editorial profile follows once we cover the company.
Share price
Price data from TradingView, possibly delayed. Not investment advice.
Comparable companies
Companies in the Biotech & Pharma sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| X4 Pharmaceuticals, Inc. | XFOR | NASDAQ | 375 Mio. USD |
| Atea Pharmaceuticals, Inc. | AVIR | NASDAQ | 376 Mio. USD |
| Emergent BioSolutions Inc. | EBS | NYSE | 373 Mio. USD |
| Mobia Medical, Inc. | MOBI | NASDAQ | 372 Mio. USD |
| Enanta Pharmaceuticals, Inc. | ENTA | NASDAQ | 366 Mio. USD |
| Prelude Therapeutics Incorporated | PRLD | NASDAQ | 366 Mio. USD |
| Evolus, Inc. | EOLS | NASDAQ | 385 Mio. USD |
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.